Key HighlightsVirax Biolabs entered into an exclusive distribution agreement with Fosun Diagnostics for six Southeast Asian countriesThe partnership encompasses the company’s ImmuneSelect immune profiling portfolio for research applicationsThailand will serve as the initial launch market with a focus on tuberculosis research before regional expansionFosun Diagnostics operates under Fosun Pharma, a healthcare giant with approximately $5.8 billion in 2025 revenuesShares of VRAX climbed more than 241% following the announcement; the company maintains a market capitalization of $2.53MOn July 9, 2026, Virax Biolabs (VRAX) revealed that its United Kingdom-based subsidiary has entered into an exclusive commercial distribution agreement spanning multiple countries with Fosun Diagnostics. The announcement triggered a dramatic 241% surge in VRAX shares during trading.Virax Biolabs Group Limited, VRAXThe partnership establishes Fosun Diagnostics as the exclusive distributor of Virax’s ImmuneSelect portfolio — a collection of research-grade immune profiling tools — throughout six key Southeast Asian territories: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.Fosun Diagnostics operates as part of Fosun Medtech, itself a segment of Fosun Pharma. With Fosun Pharma recording RMB 41.662 billion in 2025 revenues (approximately $5.8 billion), Virax has secured a partnership with a financially robust distribution network throughout the region.According to the agreement’s terms, Virax will deliver products such as ELISpot assay plates — specialized tools designed to evaluate cellular immune reactions — to Fosun through a purchase order system. The pricing model incorporates volume-based discount structures.The collaboration launches immediately with product availability and initially concentrates on tuberculosis research initiatives in Thailand, with subsequent rollout planned for the remaining five markets.The exclusive nature of the partnership depends on achieving specified minimum purchase volumes and performance benchmarks. Failure to reach these targets could result in modifications to the exclusivity provisions.The agreement structure also provides flexibility for future expansion into supplementary product categories, increased supply volumes, and possible OEM or white-label manufacturing arrangements.Understanding ImmuneSelectImmuneSelect represents Virax’s commercially available portfolio of research-only products. This line operates independently from ViraxImmune, the company’s diagnostic platform currently undergoing clinical trials and regulatory review processes.This differentiation is significant. ImmuneSelect has already achieved market availability and is attracting commercial partnerships. ViraxImmune remains in the development pipeline.James Foster, Chairman and CEO of Virax Biolabs, characterized the partnership as “a major step forward in the commercial rollout” of the ImmuneSelect platform throughout Southeast Asia.Leon Zhang, International Commercial Head for China Domestic Business at Fosun MedTech, indicated that Fosun is exploring ELISpot-based research opportunities across the regional markets.VRAX Company OverviewVirax Biolabs operates with a market capitalization of merely $2.53 million, positioning it firmly in micro-cap territory. The stock’s average daily trading volume hovers around 1.05 million shares.The latest analyst coverage on VRAX assigns a Buy rating, accompanied by a $1.00 price target.Current technical sentiment indicators classify the stock as Sell, creating a notable contrast with today’s substantial upward price movement.The 241%+ gain places significant attention on the stock, though price volatility of this magnitude is relatively common for companies operating at this market capitalization level.As of July 9, 2026, the distribution framework is operational and Fosun can immediately begin submitting purchase orders under the terms of the agreement.The post Virax Biolabs (VRAX) Stock Rockets 241% on Fosun Diagnostics Partnership appeared first on Blockonomi.